Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

8.510 +0.105 (+1.25%)
Streaming Delayed Price Updated: 9:47 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana... 
Via Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... 
Via Benzinga
Understanding Altimmune's Unusual Options Activity
Altimmune (NASDAQ:ALT) shares experienced unusual options ... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Analyzing Altimmune's Unusual Options Activity
On Tuesday, shares of Altimmune (NASDAQ:ALT) saw unusual o... 
Via Benzinga
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
H.C. Wainwright said that Altimmune Inc (NASDAQ: 
Via Benzinga
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock. 
Via InvestorPlace
Dow Set to Snap Win Streak as Tech Sector Weighs
The Dow Jones Industrial Average looks ready to snap its four-day win streak, as the tech sector's recent rout catches up with the index, which was last seen down 419 points. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Altimmune Stock Is Under Pressure Today
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug. 
Via The Motley Fool
See Why Altimmune Stock Plunged After Obesity Trial Data
Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Paratek Pharmaceuticals (NASDAQ:PRTK... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Celularity (NASDAQ:CELU) shares rose 7.0% to $7.33 during Tuesday's after-market session. The market value of their outstanding shares is at $904.9... 
Via Benzinga
ALTIMMUNE INC (ALT) Q2 2021 Earnings Call Transcript
ALT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers CohBar (NASDAQ:CWBR) stock moved upwards by 68.21% to $2.17 during Wednesday's pre-market session. The company's market cap stands at $134.0 million. The... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO 
Via Benzinga
Cramer Gives His Opinion On AT&T, Cemex And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he is not a fan of AT&T Inc. (NYSE: T). For growth, he would go with T-Mobile Us Inc (NASDAQ: TMUS) and... 
Via Benzinga
Understanding Altimmune's Unusual Options Activity
Altimmune (NASDAQ:ALT) shares experienced unusual options activity on Thursday. The stock price moved up to $8.78 following the option alert. Sentiment: BEARISH Option Type:... 
Via Benzinga
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,... 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few... 
Via Benzinga
Exposures Product Safety
Why Altimmune Is Crashing Today
The company halts development on both a COVID-19 vaccine and a drug targeting the disease. 
Via The Motley Fool
Exposures COVID-19
Mid-Afternoon Market Update: Dow Jumps 190 Points; Altimmune Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.55% to 34,482 while the NASDAQ fell 0.22% to 14,496.86. The S&P also rose, gaining 0.04% to 4,293.57. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
72 Biggest Movers From Yesterday
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Wall Street Looks to Wrap Up 2nd Quarter, 1st Half of Year with Gains
Stocks are trading near record highs this afternoon, as Wall Street looks to wrap up the second quarter and first half of 2021 with substantial wins. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume... 
Via Benzinga
Mid-Day Market Update: Barnes & Noble Education Drops Following Q4 Results; Aerovate Therapeutics Shares Surge
Midway through trading Wednesday, the Dow traded up 0.42% to 34,437.23 while the NASDAQ fell 0.14% to 14,508.18. The S&P also rose, gaining 0.06% to 4,294.30. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.